Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating four pending deals -- Sanara MedTech, Standard BioTools, Atkore, and Valaris -- for potential securities-law violations and breaches of fiduciary duties to shareholders.
For Atkore (ATKR), the firm is scrutinizing the $95.00-per-share cash sale to Prysmian S.p.A., and says it may seek increased consideration or additional disclosures on behalf of shareholders.
The release alleges insiders may receive benefits not available to ordinary shareholders and that deal terms could limit superior competing offers, but discloses no court action, filing, or deal amendment.
This is plaintiff-firm attorney advertising soliciting shareholders on a contingency basis; no new information was disclosed by Atkore or any other issuer.